Michael Mollerus
Lawyers
Filters
Uniti $1.11 billion notes offering and tender offer and consent solicitation
We advised Uniti on the high-yield notes offering, concurrent tender offer and related consent solicitation
American Well $356.8 million secondary offering
We advised Amwell on the stock offering
IHS Markit joint venture with CME Group
We are advising IHS Markit on its agreement with CME Group to combine their post-trade services into a new joint venture
IHS Markit investment in Gen II Fund Services
Davis Polk advised IHS Markit in connection with its investment in Gen II Fund Services, LLC. The strategic investment was led by General Atlantic, a leading global growth equity firm, and…
BRP Group $258.1 million follow-on offering of common stock
Davis Polk advised BRP Group, Inc. on its $258.1 million follow-on offering of 8,750,000 shares of Class A common stock. The shares of Class A common stock are listed on the Nasdaq Global…
BRP Group acquisition of Burnham Benefits Insurance Services
Davis Polk advised BRP Group, Inc. on the entry into an agreement by its indirect subsidiary, Baldwin Krystyn Sherman Partners, LLC, to acquire all of the outstanding equity interests of…
BRP Group acquisition of Armfield, Harrison & Thomas
Davis Polk advised BRP Group, Inc. on its acquisition of all of the outstanding equity interests of Armfield, Harrison & Thomas, Inc. Financial terms of the transaction were not…
IHS Markit $44 billion merger with S&P Global
Davis Polk is advising IHS Markit on its all-stock merger with S&P Global that values IHS Markit at an enterprise value of $44 billion. Under the terms of the merger agreement, each…
Bertelsmann $2.175 billion acquisition of Simon & Schuster
Davis Polk is advising Bertelsmann on the $2.175 billion acquisition by its global trade book publishing group, Penguin Random House, of Simon & Schuster from ViacomCBS. The transaction…
Stoke Therapeutics $112 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $112 million public offering of 2,500,000 shares of common stock of Stoke Therapeutics, Inc., which…